AMANTA NSE filing

Amanta Healthcare Q2FY27 Revenue Up 17.3% to ₹83.13 Cr; PAT ₹4.86 Cr

The RealCase readMedium impact Positive

Amanta Healthcare's Q2FY27 revenue grew 17.3% YoY to ₹83.13 crore, with PAT at ₹4.86 crore. EBITDA increased 21.9% YoY to ₹17.95 crore. H1FY27 revenue was ₹151.94 crore and PAT ₹8.17 crore. SteriPort Line 3 was commissioned, boosting capacity by 75%, and SVP expansion is targeted for Q1FY28.

Why it matters

The results show solid growth and capacity expansion, which are positive for the company's future performance. The impact is considered medium as it reflects performance for a single quarter and half-year period.

The market read

The company reported strong year-on-year growth in revenue and profitability, along with successful capacity expansion initiatives contributing to future growth prospects.

Amanta Healthcare Limited announced its unaudited financial results for the quarter and half year ended September 30, 2026 (Q2FY27 and H1FY27).

For Q2FY27, the company reported a revenue of ₹83.13 crore, marking a year-on-year growth of 17.3%. This growth was driven by a combination of price increases and sales from a new production line. The revenue for the half year ended H1FY27 stood at ₹151.94 crore, an increase of 11.6% YoY.

Operational performance saw a significant improvement, with EBITDA for Q2FY27 reaching ₹17.95 crore, up 21.9% YoY from ₹14.72 crore in Q2FY26. The EBITDA margin expanded by approximately 80 basis points to 21.6% from 20.8%, aided by a 4.5% YoY decline in other expenses. H1FY27 EBITDA was ₹33.13 crore, an increase of 8.4% YoY.

Profitability surged, with Profit After Tax (PAT) for Q2FY27 at ₹4.86 crore, a substantial increase from ₹1.21 crore in Q2FY26. The PAT margin for the quarter was 5.85%. PBT before exceptional items grew 39% YoY to ₹6.83 crore, while finance costs rose 13.4% to ₹5.84 crore. H1FY27 PAT was ₹8.17 crore, up 12% YoY.

The company highlighted its capacity expansion initiatives as a key driver for future growth. SteriPort Line 3 was commissioned in the first week of September 2026 at the Kheda facility, increasing SteriPort capacity by 75% from 6.6 crore to 11.6 crore bottles. This new line is expected to contribute approximately ₹60 crore in revenue in FY27 and ₹110–120 crore annually at optimal utilization. The SVP expansion, which will increase capacity from 20.9 crore to 31.7 crore units, is targeted for Q1FY28. Additionally, the 10.8 MW captive solar plant, operational since the end of Q1FY27, is projected to save around ₹9 crore annually.

Bhavesh Patel, Chairman & Managing Director, expressed confidence in building greater scale, enhancing profitability, and unlocking sustainable growth opportunities across domestic and export markets, driven by these strategic initiatives.

Filing to action

What to do with a filing like this

Amanta Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by Amanta Healthcare Limited. Read the original for the full detail.

View original filing